Abstract
As an emerging platform technology, metabolomics offers new insights into the pathomechanisms associated with complex disease conditions, including cardiovascular diseases. It also facilitates assessing the risk of developing the disease before its clinical manifestation. For this reason, metabolomics is of growing interest for understanding the pathogenesis of acute coronary syndromes (ACS), finding new biomarkers of ACS, and its associated risk management. Metabolomics-based studies in ACS have already demonstrated immense potential for biomarker discovery and mechanistic insights by identifying metabolomic signatures (e.g., branched-chain amino acids, acylcarnitines, lysophosphatidylcholines) associated with disease progression. Herein, we discuss the various metabolomics approaches and the challenges involved in metabolic profiling, focusing on ACS. Special attention has been paid to the clinical studies of metabolomics and lipidomics in ACS, with an emphasis on ischemia/reperfusion injury.
Highlights
IntroductionPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations
Our study showed that lipids and their derivatives formed the bulk of the altered metabolome in the setting of reperfusion injury in segment elevation myocardial infarction (STEMI)
We identified a panel of three lipid molecules, namely pentadecanoic acid, 18:2 carnitine, and 18:2 lysophosphatidylcholine, that can determine the extent of I/R
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. The usual cause of acute occlusion is coronary artery thrombosis caused by rupture or erosion of a high-risk, lipid-laden, atheromatous plaque [5] This sudden, reduced blood flow to the heart results in an imbalance between myocardial metabolic demands and blood supply, leading to myocardial ischemia, which is the hallmark of ACS [3,6]. Metabolomics is the new entrant in the ‘omics’ cascade in the systems biology (genomics, transcriptomics, and proteomics) approach (Figure 2) It involves high-throughput identification and quantification of small chemical compounds (
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.